Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer

Abstract

PurposeThe peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. Thyroid hormone receptor-associated proteins 220 (TRAP220) is an essential component of the TRAP/Mediator complex. The objective of this study was to clarify whether PPARγ or TRAP220 are significant prognostic markers in resectable colorectal cancer (CRC).Materials and MethodsA total of 399 patients who underwent curative resection for CRC were enrolled. We investigated the presence of PPARγ and TARP220 in CRC tissues and adjacent normal tissues by immunohistochemistry. Correlation between the expression of these factors and clinicopathologic features and survival was investigated.ResultsMedian age of the patients was 63 years (range, 22 to 87 years), and median follow-up duration 61.1 months (range, 2 to 114 months). PPARγ and TRAP220 expression showed significant correlation with depth of invasion (p=0.013 and p=0.001, respectively). Expression of TRAP220 also showed association with lymph node metastasis and TNM stage (p=0.001). Compared with patients with TRAP220 negative tumors, patients with TRAP220 positive tumors had longer 5-year disease-free survival (DFS) tendency (p=0.051). Patients who were PPARγ positive combined with TRAP220 positive had a better 5-year DFS (64.8% vs. 79.3%, p=0.013). In multivariate analysis expression of both PPARγ and TRAP220 significantly affected DFS (hazard ratio, 0.620; 95% confidence interval, 0.379 to 0.997; p=0.048).ConclusionTRAP220 may be a valuable marker for nodal metastasis and TNM stage. Tumor co-expression of PPARγ and TRAP220 represents a biomarker for good prognosis in CRC patients.

Obesity and colorectal cancer: molecular features of adipose tissue

“…4-hydroxy-2-nonenal increase PPAR gene expression and accelerate adiponectin protein degradation in adipocytes [ 65 ]. Peroxisome-proliferator-activated receptors has been also reported to arrest colorectal cancer proliferation [ 66 , 67 ], however it has also been linked to poor outcome in metastatic colorectal cancer (mCRC) [ 68 ]. 4-hydroxy-2-nonenal also upregulates prostaglandin E2 [ 69 ] and cyclooxygenase-2 (COX-2) [ 70 ], two factors associated with high proliferative colorectal cancer [ 71 ].…”

Update on genetics and diabetic retinopathy

“…Peroxisome proliferator-activated receptor gamma is a regulator of adipocyte differentiation 92 and has been implicated in the pathology of obesity, diabetes, and other disorders. 93 A meta-analysis comprising eight studies of 5,170 Caucasian and Asian patients reported that the rs1801282 (Pro12Ala) polymorphism Ala allele was negatively associated with DR in type 2 diabetes in Caucasians only ( P =0.01). 94 Similarly, a series of 573 Pakistani patients also reported a significant negative association between the Ala allele and PDR in type 2 diabetes (OR =0.4, 95% CI =0.2–0.8).…”

Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ

“…Three types of PPARs (α, β, and γ) have been identified thus far. The most studied subtype PPARγ, which was identified as a critical regulatory factor in adipogenesis, is also involved in islet cell sensitization, cell cycle arrest, and proliferation [ 8 ]. PPARγ agonist has been used for type II diabetes and related metabolic disease therapy, including obesity, hypertension, and dyslipidemia.…”